EUVIMEDEUVIMED entdecken
CrossrefInfokarte

Exploring the relevance of the matrix metalloproteinase family in ulcerative colitis patients

Laura Arosa, Djedjiga Ait Eldjoudi, Rocío Ferreiro-Iglesias, Iria Bastón-Rey, Cristina Calviño-Suárez, Marisol Porto, Laura Nieto, J Enrique Dominguez-Muñoz, Manuel Barreiro-de Acosta, Javier Conde-Aranda

Precision Clinical Medicine · 2026-11-11

DOI: 10.1093/pcmedi/pbag034 ↗
AbstractBibliografische Angaben

Abstract

Abstract Background The heterogeneity of the disease and failures in biological therapy contribute to the socioeconomic challenges derived from ulcerative colitis (UC). Therefore, it is essential to identify factors that can aid in making targeted decisions. Matrix metalloproteinases (MMPs) play a significant role in the development of intestinal inflammation. However, their potential for diagnosing, monitoring, or predicting biological therapy response has not been extensively studied. Methods We conducted in silico analyses based on the expression of all MMP-related transcripts retrieved from publicly available microarray and RNAseq datasets of UC patients. For completeness, we also evaluated the expression of MME as a potential biomarker in blood cells from a local cohort of UC patients (n = 34) using RT-qPCR, and we assessed its involvement in the proteolytic degradation of different biologic agents. Results We found that the colonic transcript levels of thirteen MMPs were dysregulated in UC patients and were highly associated with disease activity. Furthermore, the expression of these MMPs (especially MME) at the colon level is linked to difficult-to-treat patients. Additionally, the expression of MME in peripheral blood mononuclear cells (PBMCs) effectively discriminated patients who failed anti-TNF therapy. Finally, the analysis of the cleavage pattern of infliximab and vedolizumab after incubation with recombinant MME revealed no effects on the integrity of these advanced therapies. Conclusions Our findings enhance our understanding of the relationship between MMPs and UC, provide candidate biomarkers for the most aggressive phenotypes of UC, and propose an easy-to-read factor for predicting the response to anti-TNF therapy by analysing PBMCs.

Wissen, das zu Ihrer Arbeit passt.

Vom kostenlosen Einstieg über die persönliche Recherche bis zur vollständigen Research Suite.

Tarife ansehen →

Sind alle Verlagsvolltexte enthalten?

Nein. Bibliografische Nachweise, Abstracts und Volltexte sind unterschiedliche Inhalte. Ob ein Volltext verfügbar ist, hängt von der Quelle, Open Access und Ihren vorhandenen Lizenzen ab. Ein EUVIMED-Tarif ersetzt keine zusätzlichen Verlagsrechte.

Tarife ansehen →